Clinical Trials

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose symptoms included fall risk and cognitive issues, data from JAMA Neurology show.

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed that earlier initiation of the oral therapeutic led to significant disease slowing over 3 years.

Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.

Topline results from a phase 3 clinical trial showed an investigational gene therapy for young people with spinal muscular atrophy type 2 increased mobility and slowed disease progression, according to a press release from Novartis.

In this episode, host Shikha Jain, MD, speaks with Opyl co-founder Damon Rasheed about using machine learning to better predict clinical trial outcomes, handling ethical concerns surrounding AI in health care and more.

According to results from the exploratory phase 2 SHIMMER clinical trial, a small molecule oligomer antagonist improved outcomes in patients with dementia with Lewy bodies.

For individuals with recent acute cervical spinal cord injuries, treatment with a novel neuroregenerative therapeutic was nonsuperior to placebo after 6 months, according to research published in The Lancet Neurology.

LOS ANGELES — Zorevunersen led to 75% to 80% seizure reduction in patients with Dravet syndrome, according to Barry S. Ticho, MD, PhD, FACC, chief medical officer of Stoke Therapeutics.

WASHINGTON — In this video, Micaela F. Bayard, MD, discusses the shift at major conferences to include patients voices and perspectives.

Topline results from the phase 3 ReThink-ALZ study of simufilam in mild to moderate Alzheimer’s disease showed the investigational therapeutic did not meet any of its prespecified endpoints.